A primary study of artesunate accociated with carboplatin on retinoblastoma in mice
WANG Huiyan1,2,MIAO Lixia2,SUN Yanfeng2,LI Yanshan2,LIU Hongyan2, WANG Jun2,YUAN Hailian2,ZHANG Xianglan2, LIU Qiuling2
1.Xuzhou Medical College, Xuzhou 221002,China; 2.Department of Pediatrics, The General Hospital of Chinese People’s Armed Police Forces, Beijing 100039,China
Abstract：Objective This study was designed to determine the combined therapeutic effects of artesunate and carboplatin in treating retinoblastoma, compared with carboplatin alone, artesunate alone and control groups after having established newborn mice retinoblastoma model successfully. Methods (1)The cell line RBY-79 in a single-cell suspension was implanted into the right vitreous body of newborn littermates to set up a retinoblastoma xenograft model.(2)Mice bearing palpable tumors were randomly divided into four independent groups after all retinoblastoma xenograft models had been established, respectively, combined group, carboplatin group, ART group and control group. Our aims were to observe and compare the tumor size and survival time of retinoblastoma newborn mice in different groups. Results (1)Retinoblastoma xenograft models of newborn mice were successfully established and a consistent and statistically significant difference was found in the tumor weight between the right and left eyes (P<0.0001).(2)①The tumor weights in combined group, carboplatin group and ART group were significantly less than that in control (P<0.0001,P<0.0001,P=0.0015), at the same time, the survival time in these the former two groups were longer (P=0.0253,P=0.0253), that in ART group was not longer(P=0.8722). ②The tumor weights in combined group, carboplatin group were significantly less than that in ART group (P=0.0084, P=0.0015), and the survival time in the two groups were longer (P=0.0240, P=0.0239). ③The tumor weight in combined group was significantly no less than that in carboplatin group and the survival time was not longer (P=0.7980, P=1.0000). Conclusions In our study, we can find that combined treatment, carboplatin and ART can significantly inhibit the growth of retinoblastoma in vivo. However, ART does not significantly enhance the antitumor effects of carboplatin during the treatment.
王慧燕, 苗丽霞, 孙岩峰, 李彦珊, 刘红艳, 王军, 袁海莲, 张向兰, 刘秋玲. 青蒿琥酯联合卡铂治疗视网膜母细胞瘤动物实验研究[J]. 武警医学, 2015, 26(7): 716-720.
WANG Huiyan,MIAO Lixia,SUN Yanfeng,LI Yanshan,LIU Hongyan, WANG Jun,YUAN Hailian,ZHANG Xianglan, LIU Qiuling. A primary study of artesunate accociated with carboplatin on retinoblastoma in mice. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(7): 716-720.
Antoneli C B, Steinhorst F, de Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: A 13-year experience[J]. Cancer, 2003, 98(6):1292-1298.
[1]
Guillermo Chantada, Paula Schaiquevich. Management of Retinoblastoma in Children: Current Status[J]. J Pediatric Drugs, 2015, 17(3):185-198.
[10]
Baroni LV, Sampor C, Solernou V, et al. Anterior segment invasion in retinoblastoma: is it a risk factor for extraocular relapse?[J]. J Pediatr Hematol Oncol, 2014, 36(8):509-512.
[2]
Francesco Pichi, Andrea Lembo, Mariacarla, et al. Bilateral retinoblastoma: clinical presentation, management and treatment[J]. International Ophthalmology, 2013, 33(5):589-593.
[3]
Murphree A L, Villablanca J G, Deegan W F, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma[J].Arch Ophthalmol-chic, 1996, 114(11):1348-1356.
[11]
Efferth T, Giaisi M, Merling A, et al. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells[J]. PLoS One, 2007, 2(8):e693.
[4]
Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.[J]. Arch Ophthalmol, 2011, 129(11):1422-1427.
[12]
Zhao F, Wang H, Kunda P, et al. Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71[J]. Oncol Rep, 2013, 30(3):1473-1482.
[5]
Varan A, Kiratli H, Aydin B, et al. The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide[J]. Pediat Hematol Onc, 2012, 29(6):529-537.
[6]
Veal G J, Boddy A V. Carboplatin dosing in infants with retinoblastoma: A case for therapeutic drug monitoring[J]. J Clin Oncol, 2012, 30(27):3424-3029.
[13]
Cruet-Hennequart S, Villalan S, Kaczmarczyk A, et al. Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells[J]. Cell Cycle, 2009, 10(18):3043-3054.
[14]
Xiong X, Sui M, Fan W et al. Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy[J]. Cancer Biol Ther, 2007, 6(7):1067.
[7]
Qaddoumi I, Bass J K, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma[J]. J Clin Oncol, 2012, 30(10):1034-1041.
Antoneli C B, Steinhorst F, de Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: A 13-year experience[J]. Cancer, 2003, 98(6):1292-1298.
[10]
Baroni LV, Sampor C, Solernou V, et al. Anterior segment invasion in retinoblastoma: is it a risk factor for extraocular relapse?[J]. J Pediatr Hematol Oncol, 2014, 36(8):509-512.
[11]
Efferth T, Giaisi M, Merling A, et al. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells[J]. PLoS One, 2007, 2(8):e693.
[12]
Zhao F, Wang H, Kunda P, et al. Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71[J]. Oncol Rep, 2013, 30(3):1473-1482.
[13]
Cruet-Hennequart S, Villalan S, Kaczmarczyk A, et al. Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells[J]. Cell Cycle, 2009, 10(18):3043-3054.
[14]
Xiong X, Sui M, Fan W et al. Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy[J]. Cancer Biol Ther, 2007, 6(7):1067.
2015, Vol. 26 
